Bal Pharma profit and loss

Latest FY26

Revenue: ₹312cr+2.8% on FY25
EBITDA: ₹31.9cr+7.9% on FY25
Net profit: ₹6.3cr−12.2% on FY25
EPS: ₹3.95−13.4% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	334	312	303	339	304	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	1.6	1.9	2.2	2.8	0.9
	336	314	305	342	305
	173	161	150	182	179
	8.1	9.2	15.1	11.2	11.4
	−6.0	−12.2	−7.0	−1.1	−17.9
	68.7	66.5	62.4	60.4	55.3
	17.2	16.8	16.9	15.3	12.2
	11.3	11.1	9.8	10.1	9.1
	56.3	55.3	53.2	55.6	51.0
	329	308	300	333	300
	33.8	31.9	29.6	31.5	25.1
	22.4	20.8	19.8	21.5	16.0
Profit
	6.9	5.9	5.1	9.0	4.7
	6.9	5.9	5.1	9.0	4.7
	0.0	0.0	0.0	3.2	2.0
	−0.4	−0.4	−2.1	−1.6	0.1
	−0.4	−0.4	−2.1	1.6	2.1
	0.0	0.0	−0.0	0.0	0.0
	7.2	6.3	7.2	7.4	2.6
	7.2	6.3	7.2	7.4	2.6
	0.4	0.4	0.0	0.4	0.0
	7.7	6.8	7.2	7.8	2.6
	7.2	6.3	7.2	7.4	2.6
	0.0	0.0	0.0	0.1	0.0
Per share
	₹4.54	₹3.95	₹4.56	₹4.94	₹1.67
	₹4.54	₹3.95	₹4.56	₹4.96	₹1.68
Revenue detail — as filed
	—	0.0	0.0	1.2	0.1
Other comprehensive income — detail
	—	0.4	—	—	—
	—	−0.4	—	—	—
	—	6.3	7.2	7.4	2.6
	—	0.0	0.0	0.1	0.0
Per share — as-filed variants
	₹4.54	₹3.95	₹4.56	₹4.94	₹1.67
	₹4.54	₹3.95	₹4.56	₹4.96	₹1.68
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	159	154	145	147	131
	47.5%	49.3%	47.9%	43.5%	43.2%
Adjusted (ex-exceptional items) — derived
	6.9	5.9	5.1	9.0	4.7
	7.2	6.3	7.2	7.4	2.6
	₹4.54	₹3.95	₹4.56	₹4.94	₹1.67

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

BALPHARMA₹86.17

Bal Pharma Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersALPA KREBSBIO NATCAPSUQ VINEETLAB NECLIFE AAREYDRUGS BIOFILCHEM MANGALAMMcap ₹137 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	304.2	339.2	303.1	311.7	334.4
Other Income	0.9	2.8	2.2	1.9	1.6
Total Income	305.2	342.1	305.3	313.6	336.1
Expenses
+ Cost of Materials Consumed	179.2	181.6	149.9	161.0	173.4
+ Purchases of Stock-in-Trade	11.4	11.2	15.1	9.2	8.1
+ Changes in Inventories	-17.9	-1.1	-7.0	-12.2	-6.0
+ Employee Benefit Expense	55.3	60.4	62.4	66.5	68.7
+ Finance Costs	12.2	15.3	16.9	16.8	17.2
+ Depreciation & Amortisation	9.1	10.1	9.8	11.1	11.3
+ Other Expenses	51.0	55.6	53.2	55.3	56.3
Total Expenses	300.4	333.0	300.1	307.7	329.2
EBITDA	25.1	31.5	29.6	31.9	33.8
EBIT	16.0	21.5	19.8	20.8	22.4
Profit
PBT before Exceptional Items	4.7	9.0	5.1	5.9	6.9
Pretax Income	4.7	9.0	5.1	5.9	6.9
+ Current Tax	2.0	3.2	0.0	0.0	0.0
+ Deferred Tax	0.1	-1.6	-2.1	-0.4	-0.4
Tax Expense	2.1	1.6	-2.1	-0.4	-0.4
+ Share of Associates & JVs	0.0	0.0	-0.0	0.0	0.0
Net Income	2.6	7.4	7.2	6.3	7.2
+ Net Income — Continuing Ops	2.6	7.4	7.2	6.3	7.2
+ Other Comprehensive Income	0.0	0.4	0.0	0.4	0.4
Total Comprehensive Income	2.6	7.8	7.2	6.8	7.7
Net Income to Common	2.6	7.4	7.2	6.3	7.2
Minority Interest	0.0	0.1	0.0	0.0	0.0
Per Share
Basic EPS	1.67	4.94	4.56	3.95	4.54
Diluted EPS	1.68	4.96	4.56	3.95	4.54
Revenue Detail — as filed
+ Share of P&L — Partnership Firms / LLPs	0.1	1.2	0.0	0.0	—
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	0.4	—
+ Tax on Items NOT to be Reclassified	—	—	—	-0.4	—
Comprehensive Income — Owners of Parent	2.6	7.4	7.2	6.3	—
Comprehensive Income — Non-controlling Interests	0.0	0.1	0.0	0.0	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	1.67	4.94	4.56	3.95	4.54
Diluted EPS — Continuing Operations	1.68	4.96	4.56	3.95	4.54
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	131.4	147.5	145.2	153.7	158.8
Gross Margin %	43.21	43.47	47.90	49.32	47.50
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	4.7	9.0	5.1	5.9	6.9
Net Income Adj (tax-effected)	2.6	7.4	7.2	6.3	7.2
EPS Adj	1.67	4.94	4.56	3.95	4.54
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	15.7	15.8	15.9	15.9	15.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.